88485-78-3

Usage

Uses

Since the provided materials do not specify the uses of 3-(1-METHYL-CYCLOPROPYL)-3-OXO-PROPIONITRILE, it is not possible to list its applications based on the given information. However, given its classification as an organic compound and a nitrile, it may potentially be used in the following industries:
Used in Chemical Research Industry:
3-(1-METHYL-CYCLOPROPYL)-3-OXO-PROPIONITRILE is used as a research compound for studying its chemical properties, reactivity, and potential applications in various chemical reactions.
Used in Pharmaceutical Industry:
3-(1-METHYL-CYCLOPROPYL)-3-OXO-PROPIONITRILE may be used as an intermediate or building block in the synthesis of pharmaceutical compounds, given its unique structure and functional groups.
Used in Material Science:
Due to its specific functional groups and molecular structure, 3-(1-METHYL-CYCLOPROPYL)-3-OXO-PROPIONITRILE could be utilized in the development of new materials with unique properties, such as polymers or coatings.

Upstream product

• 6206-25-3 methyl 1-methylcyclopropanecarboxylate 
• 75-05-8 acetonitrile 
• 631-57-2 Acetyl cyanide 

Downstream Products

• 936240-59-4 3-(1-methylcyclopropyl)-1-(p-tolyl)-1H-pyrazol-5-amine 
• 1267851-21-7 2-(4-(6-aminopyridin-3-yl)phenyl)-N-(5-(1-methylcyclopropyl)isoxazol-3-yl)acetamide 
• 1267856-42-7 N-(5-(1-methylcyclopropyl)isoxazol-3-yl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide 

Relevant academic research and scientific papers

Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators

The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of Aβ42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting Aβ42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced Aβ42 levels in the plasma of J20 mice, in addition to reducing Aβ42 levels in the plasma and brain of Tg2576 mice.

BIARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are compounds of formula (I) wherein Ring A and R1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease

The invention relates to novel organic compounds of formula (I), and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

The present invention relates compounds of formula (I) wherein A and R1 are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.

PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.

KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.